Clinical health outcomes of Ebola virus disease survivors eight years post recovery: a cross-sectional study in Sierra Leone. Brayden G. Schindell¹, Boghuma K. Titanji², Anne W. Rimoin³, Souradet Y. Shaw⁴, Jia B. Kangbai^{5*}, Jason Kindrachuk^{1*} ¹Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada ²Division of Infectious Disease, Emory University, Atlanta, United States of America ³Department of Epidemiology, Fielding School of Public Health, University of California Los Angeles ⁴Department of Community Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada ⁵Department of Public Health, Njala University, Sierra Leone *Corresponding Author: Jason Kindrachuk (Jason.Kindrachuk@umanitoba.ca); Jia B. Kangbai (JKangbai@tulane.edu)

32 Abstract

- 33 Background The West African Ebola virus disease (EVD) epidemic that occurred between 2013-
- 34 2016 resulted in >28,000 confirmed cases and >11,000 fatalities. Thousands of survivors
- 35 necessitate an understanding of the long-term health effects and future medical needs of these
- 36 patients.

52

- 37 **Methods** A cross-sectional study of 595 EVD survivors from Sierra Leone and 403 close contacts
- 38 (n=998). An in-person survey conducted between November 2021 and March 2022 included
- demographics, clinical health symptomology assessment of each organ system and a reproductive
- 40 health assessment including sexual dysfunction question sets. The frequency of each disorder was
- examined and the association of each disorder with EVD survival was assessed.
- 42 **Results** Of 12 number of symptom types, five were reported by >50% of EVD survivors (Ocular,
- 43 Neurological, Constitutional, Genitourinary, Dermatological), and all but one were reported by
- >40% of EVD survivors. Symptom types associated with EVD survival included ENT symptoms
- 45 (AOR: 8.75, 95% CI: 5.63 13.60, p < 0.001), ocular symptoms (AOR: 7.18, 95% CI: 5.02 –
- 46 10.25, p < 0.001), dermatological symptoms (AOR: 4.16, 95% CI: 3.06 5.65, p < 0.001) and
- 47 cardiovascular symptoms (AOR: 2.96, 95% CI: 2.12 4.13, p < 0.001).
- 48 Conclusion The West Africa EVD epidemic resulted in a high prevalence of persistent health
- 49 issues among disease survivors. Continued support for survivor services in West Africa is crucial,
- 50 and future outbreak response planning should include dedicated funding to ensure adequate care
- for survivors, both during the acute phase of infection and throughout the post recovery period.

54 **Background** 55 The West African Ebola virus disease (EVD) epidemic of 2013-2016 remains the largest recorded 56 Ebola virus outbreak with 28,652 cases and 11,325 deaths[1]. An estimated 10,000-17,000 individuals recovered from EVD during this period, underscoring the need to address both the 57 immediate impacts of EVD outbreaks and the long-term consequences for survivors. [2]. Sierra 58 Leone, which reported the highest number of cases at 14,124 [1, 3]; has 3,466 registered survivors 59 60 as of 2020, though estimates suggest the total number could be over 5,000.[2]. Understanding the long-term health effects and future medical needs of survivors is crucial[4]. Most published reports 61 on the health of EVD surivors has focused on the first two years post-recovery, with only two 62 studies extending to four years[5, 6] and one study reaching 7 years. [7]. 63 The "slow and painful" recovery in survivors was first documented in the Sudan EVD outbreak in 64 65 1976[8]. More recently the West African EVD epidemic revealed that most EVD survivors 66 experience some measure of persistent health issues[7]. These symptoms and clinical findings manifest as chronic post-infectious syndromes and/or conditions characterized by immune 67 68 dysfunction[9]. The unprecedented number of survivors has raised questions about long-term health complications of EVD survivorship and the capacity of local health systems to meet these 69 70 needs[10]. Inconsistent follow-up on the management of sequelae, and limited access to healthcare 71 services have exacerbated the effects of these sequelae[11]. The lack of developed health 72 infrastructure and barriers to accessing care continue to impact the ability of EVD survivors to 73 access the required services that can help improve their overall quality of life[12, 13]. The persistent symptoms experienced by survivors makes it challenging for them to return to their 74 previous lives[14]; for example, most survivors of the Sudan Ebola virus outbreak in the 2000 75 76 Gulu, Uganda reported an inability to return to work a year after infection[15]. 77 A wide range of symptoms has been reported among EVD survivors, affecting multiple body 78 systems. The most commonly reported sequelae in the literature include fatigue, joint pain, 79 headache, muscle pain, abdominal pain, ocular complications, anorexia, memory loss, hearing loss 80 and alopecia[3, 4, 6, 7, 14, 16-25]. However, there is ongoing debate regarding the duration of 81 these sequelae, with some studies indicating symptoms wane over time while others suggest they

82

persist[5].

Our study, conducted through a cross-sectional survey, aimed to explore the persistence of sequelae among EVD survivors six to eight years post-survival. We present our findings on the prevalence of sequelae in survivors of the 2013-2016 West African EVD epidemic across Sierra Leone, comparing them to a control group of close contacts from the same regions.

Methods

83

84

85

86

87

88

89

99

100

Study Design

- 90 This national cross-sectional study was conducted in Sierra Leone from November 2021 to March
- 91 2022. It involved simultaneous recruitment and surveying across all affected districts including;
- 92 Bo, Bombali, Falaba, Kailahun, Kambia, Karene, Kenema, Koinadugu, Kono, Moyamba, Port
- 93 Loko, Pujehun, Tonkolili, Western Area Rural, and Western Area Urban [26]. Given that the
- estimated national population of EVD survivors in Sierra Leone ranges between 3,000 and 5,000,
- a sample size of 715 participants was determined to provide 95% confidence intervals for our
- outcome variables, as previously described for this population[26]. To account for potential non-
- 97 responses and ensure a minimum sample size for analysis, the recruitment target was increased to
- 98 1,000 participants.

Participants

- Eligibility criteria: To qualify as an EVD survivor, individuals were required to provide either an
- EVD discharge card or a certificate from an Ebola treatment unit in Sierra Leone, dated between
- March 2014 and March 2016, as proof of surviving the West African EVD outbreak. Eligibility
- for close contacts required them to verify their relationship to an EVD survivor or a deceased EVD
- patient. This could be established by presenting an EVD discharge card, a certificate, or a death
- certificate of the deceased EVD patient relative. Finally, all participants needed to be between the
- ages of 18 and 50 years at the time of recruitment.
- All participants consented to study participation after being fully informed about its scope,
- potential outcomes, and their right to withdraw at any time without repercussions. Consent was
- recorded by participants checking the "yes" box in the consent section at the beginning of the
- 111 survey.

A multistage sampling approach was used, where known survivors provided by the Sierra Leone Association of Ebola Survivors, were stratified by district and gender followed by random sampling within each district, close contacts were identified at the time of recruitment of EVD survivors where survivors were asked if they had any family members interested in participating and had no history of EVD. The multistage sampling started in the South of the country and proceeded counterclockwise ending in the Western region. Due to unreliable internet access in many areas, our recruitment team conducted surveys in person after recruiting participants. Translation to Krio, the most commonly spoken language after English in Sierra Leone was provided, along with assistance to those unable to read.

Instruments

112

113

114

115

116

117

118

119

120

121

- Socio-demographics were captured as previously described, and included [26] age, sex assigned
- at birth, district/province of residence, and body mass index (BMI).
- 125 Clinical health outcome variables were assessed through symptom screens where participants self-
- reported symptoms experienced in the past two weeks at the time of the survey. The symptom
- screen was organized into organ systems, and included chronic medical conditions, infections,
- ocular symptoms, ear nose and throat (ENT) symptoms, neurological symptoms, constitutional
- 129 symptoms, cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms,
- 130 genitourinary symptoms, musculoskeletal symptoms and dermatology symptoms (a full
- breakdown can be found in supplemental materials). Participants were asked if they are currently
- or recently experienced a symptom from a particular organ system and what the frequency of the
- symptom is, assessed on a 6-point Likert scale from 1 (monthly) to 6 (constantly). Both EVD
- survivors and close contacts reported symptoms experienced and were also asked whether they
- had sought medical care and are currently taking medication for symptoms.
- Both male and female participants were asked questions on sexual health. Female participants were
- given the female sexual function index (FSFI) which is a 19-item questionnaire that assesses six
- dimensions of female sexual health: desire, arousal, lubrication, orgasm, satisfaction and pain[27].
- This questionnaire was designed to measure the multidimensional nature of female sexual health.
- 140 Items were scored on either a 5-point Likert scale from 1 (Very High) to 5 (Very low/none) or a
- 6-point Likert scale from 0 (No sexual activity) to 5 (Almost always/always) over the last four

weeks, with scores ranging from 4 (Severe female sexual dysfunction) to 95 (Normal female sexual function). Female sexual arousal disorder (FSAD) is considered a tentative diagnosis with a score

of 57 or less in the FSFI.

Male participants were assessed through the international index of erectile dysfunction (IIEF), which is a 15-item questionnaire that assesses five different domains of male sexual health: erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction[28]. Items were scored on either a 5-point [1 (Very High) to 5 (Very low/none)] or a 6-point Likert scale from 0 (No sexual activity) to 5 (Almost always/always) over the last four weeks, with scores ranging from 6 (Severe male sexual dysfunction) to 75 (Normal male sexual function). screening for male sexual dysfunction is considered when scores are 36 or less on the IIEF and screening for erectile dysfunction is considered with a score of 13 or less on the erectile

Statistical Analysis

function question subset.

All statistical analyses in this study were conducted using Stata version 17·0 (College Station, TX: StataCorp LLC; 2021). Descriptive statistics included means and standard deviation, medians and interquartile ranges (IQR), and frequency and percentages, where appropriate. To examine the relationships between independent (e.g. demographic, health-related variables) and dependent variables, either the Chi-square test or Fisher's exact test was applied. For univariate, bivariate and multivariate analyses were converted into binary variables based on their respective cut-off scores. In bivariate analysis, variables that demonstrated a p-value of 0.1 or lower (using either Chi-square or Fischer's exact test) were considered for the multivariable logistic regression models. A priori, age, sex assigned at birth, province of residence, and BMI were selected to control for associations between symptomologies and EVD survival status. For the purposes of this study, statistical significance in regression models was defined as a two-tailed p-value of 0.05 or less. Results are presented in the form of adjusted odds ratios (AORs) along with associated 95% confidence intervals (CI).

Ethical considerations

Ethical approval for this study was obtained from the University of Manitoba Research Ethics Board [HS24515 (H2020:538)] and the Office of the Sierra Leone Ethics and Scientific Review Committee, Government of Sierra Leone.

Results

Participant characteristics

A total of 998 participants comprising 403 close contacts and 595 EVD survivors were included, with 533 (53.4%) male participants and 465 (46.6%) female participants[26]. Select participant demographics are described in Table 1; briefly, the average age of participants was not statistically different (p = 0.327) between close contacts (mean = 32.6 years, SD = 8.2 years) and EVD survivors (mean = 32.1 years, SD = 8.9 years). As far as general health of participants which was assessed through body mass index (BMI), there was not a significant difference (p = 0.320) between close contacts (mean = 20.8, SD = 12.1) and EVD survivors (mean = 20.2, SD = 8.0).

Table 1: Demographic characteristics of participants by close contacts and EVD survivors.

	Close EVD						
	Co	ntacts	Sur	vivors	Total		p-value
Biological Sex							≤0.001
Male	253	62.8%	280	47.1%	533	53.4%	
Female	150	37.2%	315	52.9%	465	46.6%	
Age Group							0.048
<20	25	6.2%	51	8.6%	76	7.6%	
20-24	43	10.7%	81	13.6%	124	12.4%	
25-29	73	18.1%	108	18.2%	181	18.1%	
30-34	97	24.1%	119	20.0%	216	21.6%	
35-39	82	20.3%	86	14.5%	168	16.8%	
40-44	39	9.7%	76	12.8%	115	11.5%	
45+	44	10.9%	74	12.4%	118	11.8%	
BMI							≤0.001
Classification							
Underweight	273	70.0%	334	56.8%	607	62.1%	
Normal Weight	78	20.0%	177	30.1%	255	26.1%	
Overweight	10	2.6%	27	4.6%	37	3.8%	
Obese - Class I	1	0.3%	15	2.6%	16	1.6%	
Obese - Class II	1	0.3%	10	1.7%	11	1.1%	
Obese - Class III	27	6.9%	25	4.3%	52	5.3%	
Provinces							≤0.001
Northern	13	3.2%	63	10.7%	76	7.7%	

Eastern	153	38.2%	238	40.3%	391	39.4%
Southern	80	20.0%	136	23.0%	216	21.8%
Western	92	22.9%	87	14.7%	179	18.0%
Northwest	63	15.7%	67	11.3%	130	13.1%

Main outcomes

EVD survivors were more likely to self-report symptomology across all body systems compared to close contacts (table 2) when controlled for sex, age group, BMI, and province of residence six-to-eight years after recovery. The symptom groups with the strongest association at the six-to-eight-year follow-up (table 3) were ENT symptoms (AOR: 8.75, 95% CI: 5.63 - 13.60, p < 0.001), ocular symptoms (AOR: 7.18, 95% CI: 5.02 - 10.25, p < 0.001), dermatological symptoms (AOR: 4.16, 95% CI: 3.06 - 5.65, p < 0.001) and cardiovascular symptoms (AOR: 2.96, 95% CI: 2.12 - 4.13, p < 0.001).

Table 2: Current Dermatological issues of study population by EVD survival status

	Close	Contact	EVD	Survivor	p-value
Chronic Medical Conditions	59	14.6%	162	27.2%	≤0.001
Infections	254	63.0%	411	69.1%	0.048
Ocular Symptoms	80	19.9%	336	56.5%	≤0.001
Ear, Nose and Throat Symptoms	47	11.7%	250	42.0%	≤0.001
Neurological Symptoms	235	58.3%	428	71.9%	≤0.001
Constitutional Symptoms	253	62.8%	415	69.7%	0.024
Cardiovascular Symptoms	103	25.6%	280	47.1%	≤0.001
Respiratory Symptoms	146	36.2%	291	48.9%	≤0.001
Gastrointestinal Symptoms	97	24.1%	247	41.5%	≤0.001
Genitourinary Symptoms	202	50.1%	374	62.9%	≤0.001
Musculoskeletal Symptoms	116	28.8%	257	43.2%	≤0.001
Dermatology Symptoms	130	32.3%	366	61.5%	≤0.001

Table 3: Associations with EVD survival by symptom group - Crude and Adjusted Odds Ratios (ORs) and 95% Confidence Intervals (95%CI), Logistic Regression Models

	Adjusted	
Ocular symptoms	•	
No	1	[1.00, 1.00]
Yes	7.18***	[5.02,10.25]
ENT Symptoms		
No	1	[1.00, 1.00]
Yes	8.75***	[5.63,13.60]
Neurological Symptoms		
No	1	[1.00, 1.00]
Yes	1.89***	[1.40,2.54]
Constitutional Symptoms		
No	1	[1.00, 1.00]
Yes	1.41*	[1.05,1.91]
Cardiovascular Symptoms		
No	1	[1.00, 1.00]
Yes	2.96***	[2.12,4.13]
Respiratory Symptoms		
No	1	[1.00, 1.00]
Yes	1.63**	[1.21,2.19]
Gastrointestinal Symptoms		
No	1	[1.00, 1.00]
Yes	2.15***	[1.54,3.00]
Genitourinary Symptoms		
No	1	[1.00, 1.00]
Yes	1.84***	[1.37,2.46]
Musculoskeletal Symptoms		
No	1	[1.00, 1.00]
Yes	1.93***	[1.39,2.67]
Dermatological Symptoms		
No	1	[1.00, 1.00]
Yes	4.16***	[3.06,5.65]
Observations	973	

Exponentiated coefficients; 95% confidence intervals in brackets

Commonly Reported Symptoms

ENT, Ocular, dermatological and cardiovascular symptoms were more prevalent in EVD survivors compared to close contacts. Frequencies of symptoms by symptom group are reported in Tables

^{*} p < 0.05, ** p < 0.01, *** p < 0.001

Adjusted for sex, age, BMI, province of residence.

A-D of the appendix. Logistic regression adjusting for sex, age group, BMI, and province of residence was performed on major symptoms reported (Table 4). AORs for ENT symptoms (frequencies outlined in table A of the appendix) that were highly prevalent among survivors compared to close contacts were 7.18 for reduced hearing (95% CI: 5.02 - 10.25, p < 0.001) and 8.75 for otalgia (95% CI: 5.63 - 13.60, p < 0.001). Eye pain (AOR: 1.89, 95% CI: 1.40 - 2.54, p < 0.001), itchy eyes (AOR: 1.41, 95% CI: 1.05 - 1.91, p < 0.05) and eye redness (AOR: 2.96, 95% CI: 2.12 - 4.13, p < 0.001) were prevalent ocular symptomologies (frequencies outlined in table B of the appendix). The most prevalent dermatological symptoms (frequencies outlined in table C of the appendix) were itchy skin (AOR: 1.63, 95% CI: 1.21 - 2.19, p < 0.01) rash (AOR: 2.15, 95% CI: 1.54 - 3.00, p < 0.001) alopecia (AOR: 1.84, 95% CI: 1.37 - 2.46, p < 0.001) and change in skin colour (AOR: 1.93, 95% CI: 1.39 - 2.67, p < 0.001). The most reported cardiovascular symptoms (frequencies outlined in table D of the appendix) were chest pain (AOR: 5.39, 95% CI: 3.29 - 8.82, p < 0.001) and leg pain (AOR: 4.16, 95% CI: 3.06 - 5.65, p < 0.001).

Table 4: Associations with EVD survival by symptom – Crude and Adjusted Odds Ratios (AORs) and 95% Confidence Intervals (95%CI),

221 Logistic Regression Models

	AOR	
Reduced hearing		
No	1	[1.00, 1.00]
Yes	7.18***	[5.02,10.25]
Pain in ears		
No	1	[1.00, 1.00]
Yes	8.75***	[5.63,13.60]
Eye pain		
No	1	[1.00, 1.00]
Yes	1.89***	[1.40,2.54]
Itchy eyes		
No	1	[1.00, 1.00]
Yes	1.41*	[1.05,1.91]
Eye redness		
No	1	[1.00, 1.00]
Yes	2.96***	[2.12,4.13]
Itchy skin		
No	1	[1.00, 1.00]
Yes	1.63**	[1.21,2.19]
Rash		
No	1	[1.00, 1.00]
Yes	2.15***	[1.54,3.00]
Alopecia		_
No	1	[1.00, 1.00]

Yes	1.84***	[1.37,2.46]
Change in skin color		
No	1	[1.00, 1.00]
Yes	1.93***	[1.39,2.67]
Chest pain		
No	1	[1.00,1.00]
Yes	5.39***	[3.29,8.82]
Leg pain		
No	1	[1.00,1.00]
Yes	4.16***	[3.06,5.65]
Observations	973	

²²² Exponentiated coefficients; 95% confidence intervals in brackets

Reproductive Health Assessment

Amongst female participants, significantly more EVD survivors (n=56, 19.7%, p≤0.001) expressed decreased interest in sexual intercourse (table E appendix) than close contacts (n=6, 5.0%). The same was not observed for male EVD survivors (n=24, 9.3%, p≤0.086) and close contacts (n=11, 5.2%). Logistic regression analysis was performed for reproductive health (table 5 and 6) under the same conditions as described in earlier sections, stratified by sex at birth. EVD survival was significantly associated with several reproductive health variables, including sexual intercourse (AOR: 5.53, 95% CI: 3.04 – 10.07), decreased interest in sexual intercourse (AOR: 3.64, 95% CI: 1.34 – 9.86), irregular periods (AOR: 3.07, 95% CI: 1.75 – 5.36) and no recent pregnancies (AOR: 3.53, 95% CI: 1.69 – 7.34). For males, EVD survivorship was associated with reporting no conceived pregnancies in the last year (AOR: 2.73, 95% CI: 1.29-5.81).

Table 5: Associations Female Reproductive and Sexual Health Associations with EVD survival – Crude and Adjusted Odds Ratios (AORs) and 95% Confidence Intervals (95%CI), Logistic Regression Models

	AOR	
Sexual Intercourse in the		
Last Year		
No	5.53***	[3.04,10.07]
Yes	1	[1.00,1.00]
Decreased Interest in		
Sexual Intercourse		
No	1	[1.00, 1.00]
Yes	3.64*	[1.34,9.86]
Menstruation in the Last		
Year		

^{*} p < 0.05, ** p < 0.01, *** p < 0.001

Adjusted for sex, age, BMI, province of residence.

Regular Period	1	[1.00,1.00]
Irregular Period	3.07***	[1.75,5.36]
No Period	1.56	[0.57,4.27]
Pregnant in the Last Year		
No	3.53***	[1.69,7.34]
Yes	1	[1.00, 1.00]
Given Birth		
No	1	[1.00, 1.00]
Yes	1.28	[0.74,2.20]
Observations	384	

²⁴⁰ Exponentiated coefficients; 95% confidence intervals in brackets

244245

246

247

248

250

251

252

253

254

255

Table 6: Associations Male Reproductive and Sexual Health Associations with EVD survival – Crude and Adjusted Odds Ratios (AORs) and 95% Confidence Intervals (95%CI), Logistic Regression Models

	AOR	
Sexual Intercourse in the		
Last Year		
No	1.46	[0.93, 2.29]
Yes	1	[1.00, 1.00]
Decreased Interest in		
Sexual Intercourse		
No	1	[1.00, 1.00]
Yes	1.75	[0.75, 4.10]
Conceived child with		
partner in the Last Year		
No	2.73**	[1.29,5.81]
Yes	1	[1.00,1.00]
Fathered a child		
No	1	[1.00, 1.00]
Yes	1.22	[0.74,2.01]
Observations	463	

Exponentiated coefficients; 95% confidence intervals in brackets

Discussion

In this study, we present the most prevalent clinical symptoms experienced by EVD survivors compared to their close contacts, 6-8 years after the West Africa EVD outbreak. Other studies have reported on persistent ocular manifestations in survivors dating to the Kikwit outbreak, where a two year follow-up study identified ocular pain, blurry vision and light sensitivity[24]. The same

^{241 *} p < 0.05, ** p < 0.01, *** p < 0.001

Adjusted for sex, age, BMI, province of residence.

^{*} p < 0.05, ** p < 0.01, *** p < 0.001

Adjusted for sex, age, BMI, province of residence.

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

study also identified the presence of highly prevalent symptoms including joint pain, hearing loss and fatigue[24]. These symptoms continue to be among the most reported sequelae in available literature and were among the most reported in this study[3, 4, 6, 7, 14, 16-25]. There are several reports on clinical health outcomes in the immediate aftermath of the West African EVD epidemic, however, there has been a paucity of information on the longer-term clinical health outcomes of EVD survivors. While it has previously been reported that persistence of sequelae diminishes over time, our results suggest that in Sierra Leone this has not been the case[5, 7, 16] (table 2). We report on five symptom types reported by >50% of EVD survivors 6-8 years post recovery, and all but one reported by >40% of EVD survivors[5]. Recent studies including by Wohl et al., the only other published study with long term follow-up of survivors in Liberia included a study population of 326 participants who were followed up to five years from Ebola treatment Center (ETC) discharge[7]. It is difficult to compare the findings between two studies in different countries utilizing different survey tools, however some of the differences are notable in results at 5+ years post recovery; including fatigue (12.2% vs 20.2% reported in table I of appendix), headache (20.3% vs 64.4% in table H of appendix), hearing loss (2.8% vs 13.9% in table A of appendix), joint pain (15.8% vs 26.7% in table J of appendix), muscle pain (0.0% vs 5.5% in table J of appendix) and vision impairment (17.4% vs 8.1% in table B of appendix). The experiences reported by survivors of the same epidemic in a similar time frame of assessment demonstrate the variable experiences of long-term sequelae by survivors based on their geographic location and environment. It is challenging to hypothesize on which factors may account for the differences observed in the rates of these various symptomologies (As listed in table 2); however, population sample size, living conditions and health care access are plausible factors that may affect these differences observed. When comparing symptomology to reported rates from another recent study conducted by Bond et al. in Eastern Sierra Leone, with 375 EVD survivors and 1040 close contacts, similar findings of physical symptoms were significantly more commonly reported by survivors compared with close contacts[17]. This study was conducted between 1.6 and 3.3 years after discharge from ETCs suggesting that symptomology rates have remained elevated and stable over the subsequent 3-5 years from the initial recovery period to the 6-8-year follow-up time point reported in our study. Similar findings to those presented here have previously been observed in West Africa regarding reproductive health of female and male EVD survivors. A study conducted

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

from January to April 2016 in Montserrado county, Liberia found that 16.2% of male EVD survivors surveyed reported testicular pain or erectile dysfunction, while 19.7% of female EVD survivors reported having menstrual problems including amenorrhoea and other menstrual irregularities[14]. Another study conducted in February 2015 in Bombali District, Sierra Leone found that 2.2% of female EVD survivors reported a menstrual disorder and 3.4% of male EVD survivors reported erectile dysfunction[29]. A study conducted in Liberia between 2016 and 2017 including 111 female participants from Monrovia, reported 25.7% of female participants had irregular menstruation of unknown cause[30]. The same group reported in a qualitative study including 69 women, that 50% of female survivors from Liberia had reported decreased sexual libido following recovery with several women also reporting pain during intercourse, and 46% of participants reporting some of menstrual irregularity[31]. We made similar observations in our study (table 6 and tables E and F of the appendix,) with female survivors also reporting menstrual changes and changes in sexual libido. Reproductive health changes experienced by EVD survivors remain understudied. Additionally, there are long-term social and mental health effects, as we have previously reported in this cohort [26, 32]. Many survivors experience social isolation, with their relationship status being directly associated with stigmatization. The mental health effects are also profound, with 45.7% of EVD survivors reporting post-traumatic stress disorder related to their Ebola experience and its impact on their interpersonal relationships [26, 32]. There is a lack of data on the factors related to the host and the disease that predict symptoms and the mechanisms behind their persistence. Understanding the viral and immune-related mediators may help develop targeted treatment plans to address these chronic symptoms for EVD survivors[24, 33]. Investigations into the mechanisms that explain the sequelae reported by EVD survivors have been limited. However, some studies have found associations with various symptoms[24, 33]. A 23month follow-up study identified increased blood markers of inflammation, intestinal tissue damage, T-cell and B-cell activation and a depletion of circulating dendritic cells[9]. Additionally the level of adaptive immune cells remained highly elevated two years after recovery in EVD survivors tested[9]. The study also found that immune cell phenotypes shifted towards activated cytotoxic T cells, exhausted B cells, proinflammatory monocytes and non-classical NK cells, which are common in chronic viral infections. Elevated levels of inflammatory markers and activation of antiviral pathways have been reported to persist in the absence of detectable virus[9]. Specifically D dimer, IFN-y, IL-8 and TNF-alpha were shown to persist. Markers of chronic

immune activation such as CCL5 and sCD40L, and markers of potential liver and kidney damage, including higher levels of alanine transaminase, aspartate transaminase, bilirubin, creatine and creatine kinase, were also found to persist[6, 9, 34]. These findings demonstrate that the chronic effects of EVD infection continue to manifest in physical symptoms that severely impact the dayto-day lives of EVD survivors across all organ systems. Symptoms have made it difficult to get back to their prior lives they lived [14]. Among the most reported symptoms in this study were dermatological issues, including itchy skin, rashes, alopecia, and hyperpigmentation. While these symptoms have been previously reported, there are no recent reports discussing them in detail[3, 14]. Given their high visibility and prevalence (61.5% in this cohort and previously reported at 48.8%), these symptoms can be highly discriminating and visible sequelae among survivors[14]. Previous reports suggest reintegration into the community was limited[20], with many survivors reporting a lower socioeconomic status than prior to EVD (90%), less favourable work (79%) and worse psychological status (60%)[20]. In Kikwit, Democratic Republic of the Congo 70% of survivors indicated capacity to work was worse 21 months following infection compared to before suggesting that the physical segualae, as observed in this study affects their ability to return to their prior lives[24]. 60.9% of women seeking care at the survivor clinic in Kenema were female[22]. Some survivors may benefit from rheumatologic, musculoskeletal, or neurologic evaluation in the recovery phase[11]. A limitation of this study is the reliance on self-reporting symptomologies without formal assessment of impairments through physical examinations. This was mitigated by using validated standardized questionnaires with objective measurements of symptoms and direct comparisons to a control population. The study's cross-sectional design limited our ability to establish cause-andeffect relationships or analyse change over time meaningfully. Recruiting close contacts as a control population allowed us to match the economic, geographic and social experiences between the two study groups as much as possible. Exploratory analyses conducted may have increased the risk of type I error in this study. It is possible that individuals with more severe symptoms were more likely to participate, but this was mitigated through broad recruitment both in terms of the number of survivors and their geographic distribution.

Conclusions

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

Our results indicate that many, if not most, EVD survivors from the West Africa EVD epidemic continue to experience persistent health issues. Factors such as inconsistent follow up on the management of sequelae[11], limited access to healthcare services difficulty in obtaining necessary mediations or follow up care, poor health seeking behavior, and inadequate access to quality healthcare have compounded the challenges in managing these symptoms.[35] Additionally, the withdrawal of support without a proper transition period has led to issues like food insecurity, further exacerbating the long-term sequelae observed in our study.

Given the chronic nature of EVD- associated sequelae, it is crucial to consider funding and strengthening existing medical infrastructure in affected countries to ensure long-term follow up and care.[25]. Sustained support for survivor services in West Africa is essential, and funding for survivor follow-up should be integrated into future outbreak response planning planning provide to provide adequate care both during acute infection and throughout the post-recovery period[25].

Contributors

JK and JBK conceived the study, while BGS, JBK, SYS, and JK designed the study. JBK lead the recruitment and in-country support in Sierra Leone. BGS BKT SYS analysed the data. BGS prepared the manuscript. JK supervised the study, analysis and writing process. All authors contributed to the intellectual content of the manuscript and read and approved the final version of the manuscript.

Declaration of Interest

The authors declare no competing interests.

Data Sharing

Due to the sensitive nature of our survey and the involvement of human participants we did not receive approval to collect raw participant identified data from The University of Manitoba Research Ethics Board or the Sierra Leone Ethics and Scientific Review Committee. While participants additionally consented to the study with the knowledge that their data was collected in an anonymized manner with the only record of participants being record of payment only accessible by JK and JBK and securely stored in an encrypted file. Upon reasonable request however, the anonymized raw study data can be made available through the following persons; 1)

- from UM REB by contacting the office (Email: bannreb@umanitoba.ca) 2) Edward Foday,
- 380 Research and Publications Specialist, Sierra Leone Ethics and Scientific Review Committee,
- Directorate of Policy, Planning and Information, Ministry of Health and Sanitation, Fifth Floor,
- Youyi Building, East Wing, Freetown, Sierra Leone (Email: efoday@health.gov.sl).

Acknowledgements

383

384

394

395

400

401

- We would like to thank our funding sources JK is funded by a Tier 2 Canada Research Chair in
- the Molecular Pathogenesis of Emerging and Re-Emerging Viruses provided by the Canadian
- Institutes of Health Research (Grant no. 950-231498), and the Canadian Institutes of Health
- 388 Research (Grant no. PJT-175098). BKT has received funding support from NIH Building
- 389 Interdisciplinary Careers in Women's Health (BIRCWH) Grant (K12HD085850) and from
- Emory's Center AIDS Research Grant (P30 AI050409). We would like to thank both the EVD
- survivor and close contact participants of this study. We would also like to thank the participant
- recruiters for their work and support. We would also like to thank the Sierra Leone Ebola Survivors
- 393 Association.

Abbreviations

- EVD (Ebola virus disease); BMI (body mass index); ENT (ear, nose and throat); FSFI (Female
- sexual function index); FSAD (Female sexual arousal disorder); IIEF (International index of
- erectile function); IQR (Interquartile range); AOR (Adjusted odds ratio); CI (Confidence
- interval); ETC (Ebola treatment Centre)

References

- 402 1. Centers for Disease Control and Prevention. History of Ebola Virus Disease (EVD)
- 403 Outbreaks 2024 [December July 21, 2024]. Available from:
- 404 https://www.cdc.gov/vhf/ebola/history/chronology.html#print.
- 405 2. Alva S, Davis N, Stan L, Pivato I, Sanderson J. Conducting mixed-methods research with
- 406 Ebola survivors in a complex setting in Sierra Leone. BMC Public Health. 2020;20(1):1346. Epub
- 407 2020/09/05. doi: 10.1186/s12889-020-09469-9. PubMed PMID: 32883281; PubMed Central
- 408 PMCID: PMCPMC7470604.
- 409 3. Tiffany A, Vetter P, Mattia J, Dayder J-A, Bartsch M, Kasztura M, et al. Ebola virus disease
- 410 complications as experienced by survivors in Sierra Leone. Clin Infect Dis. 2016;62(11):1360-6.
- 411 doi: 10.1093/cid/ciw158.

- 412 4. Clark DV, Kibuuka H, Millard M, Wakabi S, Lukwago L, Taylor A, et al. Long-term
- sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet
- 414 Infect Dis. 2015;15(8):905-12. Epub 2015/04/26. doi: 10.1016/S1473-3099(15)70152-0.
- 415 PubMed PMID: 25910637.
- 416 5. Diallo MSK, Toure A, Sow MS, Kpamou C, Keita AK, Taverne B, et al. Understanding long-
- 417 term evolution and predictors of sequelae of Ebola virus disease survivors in Guinea: a 48-
- 418 month prospective, longitudinal cohort study (PostEboGui). Clin Infect Dis. 2021;73(12):2166-
- 419 74. doi: 10.1093/cid/ciab168.
- 420 6. Tozay S, Fischer WA, Wohl DA, Kilpatrick K, Zou F, Reeves E, et al. Long-term
- 421 complications of Ebola virus disease: prevalence and predictors of major symptoms and the role
- 422 of inflammation. Clin Infect Dis. 2020;71(7):1749-55. doi: 10.1093/cid/ciz1062.
- 423 7. Wohl DA, Fischer WA, Mei W, Zou F, Tozay S, Reeves E, et al. Post-Ebola Symptoms 7
- 424 Years after Infection: The natural history of Long Ebola. Clin Infect Dis. 2022. Epub 2022/09/07.
- 425 doi: 10.1093/cid/ciac732. PubMed PMID: 36065768.
- 426 8. World Health Organization. Ebola haemorrhagic fever in Sudan, 1976. Report of a
- 427 WHO/International Study Team. Bull World Health Organ. 1978;56:247-70.
- 428 9. Wiedemann A, Foucat E, Hocini H, Lefebvre C, Hejblum BP, Durand M, et al. Long-lasting
- severe immune dysfunction in Ebola virus disease survivors. Nat Commun. 2020;11:3730. doi:
- 430 10.1038/s41467-020-17489-7.
- 431 10. Secor A, Macauley R, Stan L, Kagone M, Sidikiba S, Sow S, et al. Mental health among
- 432 Ebola survivors in Liberia, Sierra Leone and Guinea: results from a cross-sectional study. BMJ
- 433 Open. 2020;10(5):e035217. Epub 2020/05/29. doi: 10.1136/bmjopen-2019-035217. PubMed
- 434 PMID: 32461296; PubMed Central PMCID: PMCPMC7259862.
- 435 11. Djomealeu ML, Rogers AB, Barrie MB, Rutherford GW, Weiser SD, Kelly JD. Long-term
- 436 consequences of food insecurity among Ebola virus disease-affected households after the 2013-
- 437 2016 epidemic in rural communities of Kono District, Sierra Leone: a qualitative study. PLOS
- 438 Glob Public Health. 2022;2(10):e0000770. doi: 10.1371/journal.pgph.0000770.
- 439 12. World Health Organization. Mental health atlas: 2011: World Health Organization; 2011.
- 440 13. Mahase E. Sierra Leone: Ebola and war survivors failed by lack of mental health services,
- 441 Amnesty finds. BMJ. 2021;373:n1381. Epub 2021/05/29. doi: 10.1136/bmj.n1381. PubMed
- 442 PMID: 34045237.
- 443 14. Wilson HW, Amo-Addae M, Kenu E, Ilesanmi OS, Ameme DK, Sackey SO. Post-Ebola
- 444 Syndrome among Ebola Virus Disease Survivors in Montserrado County, Liberia 2016. Biomed
- 445 Res Int. 2018;2018:1909410. Epub 2018/07/28. doi: 10.1155/2018/1909410. PubMed PMID:
- 446 30050920; PubMed Central PMCID: PMCPMC6046154.
- 447 15. Wendo C. Caring for the survivors of Uganda's Ebola epidemic one year on. Lancet.
- 448 2001;358(9290):1350. doi: 10.1016/S0140-6736(01)06467-4.
- 449 16. Group PIS, Sneller MC, Reilly C, Badio M, Bishop RJ, Eghrari AO, et al. A Longitudinal
- 450 Study of Ebola Sequelae in Liberia. N Engl J Med. 2019;380(10):924-34. Epub 2019/03/12. doi:
- 451 10.1056/NEJMoa1805435. PubMed PMID: 30855742; PubMed Central PMCID:
- 452 PMCPMC6478393.
- 453 17. Bond NG, Grant DS, Himmelfarb ST, Engel EJ, Al-Hasan F, Gbakie M, et al. Post-Ebola
- 454 Syndrome Presents With Multiple Overlapping Symptom Clusters: Evidence From an Ongoing
- 455 Cohort Study in Eastern Sierra Leone. Clin Infect Dis. 2021;73(6):1046-54. Epub 2021/04/07.

- doi: 10.1093/cid/ciab267. PubMed PMID: 33822010; PubMed Central PMCID:
- 457 PMCPMC8442780.
- 458 18. Mudalegundi S, Ross RD, Larbelee J, Amegashie F, Dolo RF, Prakalapakorn GS, et al.
- 459 Long-term decrease in intraocular pressure in survivors of Ebola virus disease in th partnership
- 460 for research on vaccines and infectious diseases in liberia (PREVAIL) III study. Ophthalmol Sci.
- 461 2023;3(2):100238. doi: 10.1016/j.xops.2022.100238.
- 462 19. Chertow DS. Understanding long-term effects of Ebola virus Disease. Nat Medicine.
- 463 2019;25:711-5. doi: 10.1038/s41591-019-0444-0.
- 464 20. Delamou A, Camara BS, Kolie JP, Guemou AD, Haba NY, Marquez S, et al. Profile and
- reintegration experience of Ebola survivors in Guinea: a cross-sectional study. Trop Med Int
- 466 Health. 2017;22(3):254-60. Epub 2016/12/10. doi: 10.1111/tmi.12825. PubMed PMID:
- 467 27935657.
- 468 21. Epstein L, Wong KK, Kallen AJ, Uyeki TM. Port-Ebola signs and symptoms in U.S.
- survivors. New England Journal of Medicine. 2015;373(25):2484-6. doi:
- 470 10.1056/NEJMc1506576.
- 471 22. Mohammed H, Vandy AO, Stretch R, Otieno D, Prajapati M, Calderon M, et al. Sequelae
- and Other Conditions in Ebola Virus Disease Survivors, Sierra Leone, 2015. Emerg Infect Dis.
- 473 2017;23(1):66-73. Epub 2016/12/17. doi: 10.3201/eid2301.160631. PubMed PMID: 27983503;
- 474 PubMed Central PMCID: PMCPMC5176247.
- 475 23. Nanyonga M, Saidu J, Ramsay A, Shindo N, Bausch DG. Sequelae of Ebola Virus Disease,
- 476 Kenema District, Sierra Leone. Clin Infect Dis. 2016;62(1):125-6. Epub 2015/09/10. doi:
- 477 10.1093/cid/civ795. PubMed PMID: 26349549.
- 478 24. Rowe AK, Bertolli J, Khan AS, Mukunu R, Muyembe-Tamfum JJ, Bressler D, et al. Clinical,
- 479 virologic, and immunologic follow-up of convalecent Ebola hemorrhagic fever patients and their
- 480 household contacts, in Kikwit, Democratic Republic of the Congo. J Infect Dis. 1999;179:S28-35.
- 481 25. de St Maurice A, Ervin E, Orone R, Choi M, Dokubo EK, Rollin PE, et al. Care of Ebola
- 482 Survivors and Factors Associated With Clinical Sequelae-Monrovia, Liberia. Open Forum Infect
- 483 Dis. 2018;5(10):ofy239. Epub 2018/11/06. doi: 10.1093/ofid/ofy239. PubMed PMID: 30386807;
- 484 PubMed Central PMCID: PMCPMC6202424.
- 485 26. Schindell BG, Kangbai JB, Shaw SY, Kindrachuk J. Stigmatization of Ebola virus disease
- 486 survivors in 2022, a cross-sectional study of survivors in Sierra Leone. J Infect Public Health.
- 487 2023. doi: 10.1016/j.jiph.2023.10.025.
- 488 27. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexul
- 489 Function Index (FSFI): A multidimensional self-report instrument for the assessment of Female
- 490 Sexual Function. J Sex Marital Ther. 2000;26:191-208.
- 491 28. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international
- index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction.
- 493 Urology. 1997;49(6):822-30. doi: 10.1016/s0090-4295(97)00238-0.
- 494 29. Nabena EP, Bakare WA, Ilesanmi OS, Anyanwu R, Akuechiama JC, Inyang SEJ, et al.
- 495 Health problems of Ebola virus disease survivors in Sierra Leone, 2015: making a case for
- follow-up care after discharge from Ebola treatment centres. Open Med J. 2015;2:53-8. doi:
- 497 10.2174/1874220301401010053.
- 498 30. Godwin CL, Wohl DA, Fischer Nd WA, Singh K, Hawks DA, Devore EE, et al. Reproductive
- 499 health sequelae among women who survived Ebola virus disease in Liberia. Int J Gynaecol

- 500 Obstet. 2019;146(2):212-7. Epub 2019/05/11. doi: 10.1002/ijgo.12858. PubMed PMID:
- 31074837; PubMed Central PMCID: PMCPMC6675397.
- 502 31. Godwin CL, Buller A, Bentley M, Singh K. Understanding the personal relationships and
- reproductive health changes of female survivors of Ebola infection in Liberia. In: Schwartz DA,
- Anoko JN, Abramowitz SA, editors. Pregnant in the time of Ebola: women and their children in
- the 2013-2015 West African epidemic. Cham, Switzerland: Springer; 2019. p. 103-20.
- 506 32. Schindell BG, Fredborg B, Kowalec K, Shaw SY, Kangbai JB, Kindrachuk J. The state of
- 507 mental health among Ebola virus disease survivors through a cross-sectional study in Sierra
- 508 Leone. BMJ Glob Health. 2024;9:e015098. doi: 10.1136/bmjgh-2024-015098.
- 509 33. Mattia JG, Vandy MJ, Chang JC, Platt DE, Dierberg K, Bauch DG, et al. Early clinical
- 510 sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. Lancet Infect Dis.
- 511 2016;16:331-38. doi: 10.1016/S1473-3099(15)00489-2.
- 512 34. Wadoum REG, Sevalie S, Kargbo MB, Clarke A, Bangura S, Kargbo M, et al. Identification
- of laboratory biomarkers for early detection and clinical management of post-acute syndrome
- among survivors of the 2013-2016 West Africa Ebola Outbreak in Sierra Leone. J Blood Med.
- 515 2023;11(14):119-32. doi: 10.2147/JBM.S371239.

- 516 35. Jagadesh S, Sevalie S, Fatoma R, Sesay F, Sahr F, Faragher B, et al. Disability Among
- 517 Ebola Survivors and Their Close Contacts in Sierra Leone: A Retrospective Case-Controlled
- 518 Cohort Study. Clin Infect Dis. 2018;66(1):131-3. Epub 2017/10/12. doi: 10.1093/cid/cix705.
- PubMed PMID: 29020205; PubMed Central PMCID: PMCPMC5833946.